menu
    • menu
    [{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Recombinant Bovine Intestinal Alkaline Phosphatase","moa":"Intestinal alkaline phosphatase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Synthetic Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Synthetic Biologics"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Lumos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ibutamoren","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ABBV-CLS-7262","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Undislcosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Derm-Biome Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"CKDB-501A","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"DIMERx","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ DIMERx","highestDevelopmentStatusID":"14","companyTruncated":"Massachusetts General Hospital \/ DIMERx"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"14","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Massachusetts General Hospital","highestDevelopmentStatusID":"14","companyTruncated":"Massachusetts General Hospital \/ Massachusetts General Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Massachusetts General Hospital

    Menu

    Massachusetts General Hospital

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alzamend Neuro Partners with MGH for Phase II Trial of AL001 in Bipolar Disorder

                            Details : Through the partnership, Alzamend Neuro will focus on the clinical development of lead product AL001 (lithium salicylate proline) for treating bipolar disorder.

                            Brand Name : AL001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alzamend Partners with MGH For Phase II AL001 Alzheimer's Clinical Trial

                            Details : The partnership aims to conduct a Phase II trial of AL001, a novel lithium-delivery system via a therapeutic combination of lithium, salicylate and L-proline, for patients with Alzheimer’s.

                            Brand Name : AL001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMX-201

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : DIMERx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            DIMERx Secures Global Rights to Novel Amino Acid Prodrug Developed at MGH

                            Details : Under the term of license agreement, DIMERx aims to advance the development of AMX-201, currently being evaluated in early-stage trials for treating challenging paradigms across various rare diseases.

                            Brand Name : AMX-201

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : AMX-201

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : DIMERx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CKDB-501A

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Healis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Healis Therapeutics Announces Collaboration with MGH and Harvard Medical School

                            Details : The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions

                            Brand Name : CKDB-501A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : CKDB-501A

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Healis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Recipient : Derm-Biome Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study

                            Details : The collaboration aims to study the second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Recipient : Derm-Biome Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Tryp Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS ...

                            Details : TRP-8802 (Oral psilocybin) in patients withIrritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with Irritable Bowel Syndrome.

                            Brand Name : TRP-8802

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 13, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Tryp Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciprofloxacin,Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : NeuroSense Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating ...

                            Details : NeuroSense & Massachusetts General Hospital will explore the neurotherapeutic effects of PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue. PrimeC is a novel unique fixed-dose combination of ciprofloxacin and celecoxib.

                            Brand Name : PrimeC

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Ciprofloxacin,Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : NeuroSense Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undislcosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Voltron Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the M...

                            Details : Under the terms of the agreement, Harvard Medical School will initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing ...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 28, 2023

                            Lead Product(s) : Undislcosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Voltron Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-CLS-7262

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial

                            Details : ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress...

                            Brand Name : ABBV-CLS-7262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : ABBV-CLS-7262

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Recipient : Lumos Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM...

                            Details : LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adu...

                            Brand Name : LUM-201

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Recipient : Lumos Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth